BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862
853 results:

  • 1. BET inhibition induces synthetic lethality in pten deficient colorectal cancers via dual action on p21
    Ren G; Chen J; Pu Y; Yang EJ; Tao S; Mou PK; Chen LJ; Zhu W; Chan KL; Luo G; Deng C; Shim JS
    Int J Biol Sci; 2024; 20(6):1978-1991. PubMed ID: 38617536
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. cancer-associated fibroblasts drive colorectal cancer cell progression through exosomal miR-20a-5p-mediated targeting of pten and stimulating interleukin-6 production.
    Ghofrani-Shahpar M; Pakravan K; Razmara E; Amooie F; Mahmoudian M; Heshmati M; Babashah S
    BMC Cancer; 2024 Apr; 24(1):400. PubMed ID: 38561726
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
    Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. FBXO8 is a novel prognostic biomarker in different molecular subtypes of breast cancer and suppresses breast cancer progression by targeting c-MYC.
    Khan AJ; Man S; Abbas M; Liu S; Zhang F
    Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130577. PubMed ID: 38301858
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic colorectal cancer (PanaMa Phase II Trial, AIO KRK 0212).
    Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
    Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Knocking down of lncRNA SBF2-AS1 inhibits proliferation, invasion and induces apoptosis of colorectal cancer through regulating pten.
    Cai Y; Yan H; Wang F; Xie L
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):201-205. PubMed ID: 38279439
    [TBL] [Abstract] [Full Text] [Related]  

  • 7.
    Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Clinical-Molecular characteristics and Post-Translational modifications of colorectal cancer in north China: Implications for future targeted therapies.
    Chi Y; Yuan H; Fan Q; Wang Z; Niu Z; Yu J; Yuan D
    Gene; 2024 Mar; 899():148134. PubMed ID: 38185290
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. De novo NAD
    Wan J; Cheng C; Hu J; Huang H; Han Q; Jie Z; Zou Q; Shi JH; Yu X
    Cell Rep; 2023 Dec; 42(12):113518. PubMed ID: 38041812
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
    Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
    Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. CLDN6 inhibits colorectal cancer proliferation dependent on restraining p53 ubiquitination via ZO-1/pten axis.
    Dong Y; Xu W; Qi D; Qu H; Jin Q; Sun M; Wang X; Quan C
    Cell Signal; 2023 Dec; 112():110930. PubMed ID: 37852424
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The Role of microRNAs in Regulating cancer Cell Response to Oxaliplatin-Containing Regimens.
    Tavakoli Pirzaman A; Ebrahimzadeh Pirshahid M; Babajani B; Rahmati A; Niknezhad S; Hosseinzadeh R; Taheri M; Ebrahimi-Zadeh F; Doostmohamadian S; Kazemi S
    Technol Cancer Res Treat; 2023; 22():15330338231206003. PubMed ID: 37849311
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]    [Full Text] [Related]  

  • 16. TRIP6 disrupts tight junctions to promote metastasis and drug resistance and is a therapeutic target in colorectal cancer.
    Gou H; Wong CC; Chen H; Shang H; Su H; Zhai J; Liu W; Liu W; Sun D; Wang X; Yu J
    Cancer Lett; 2023 Dec; 578():216438. PubMed ID: 37827326
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Chanling Gao suppresses colorectal cancer via PI3K/Akt/mTOR pathway modulation and enhances quality of survival.
    Chen G; Tian TT; Wang FQ; Pan CS; Sun K; Wang XY; Yang B; Yang Z; Tang DX; Han JY
    Environ Toxicol; 2024 Mar; 39(3):1107-1118. PubMed ID: 37823609
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. pten-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study.
    Mihara Y; Hirasaki M; Horita Y; Fujino T; Fukushima H; Kamakura Y; Uranishi K; Hirano Y; Ryozawa S; Yasuda M; Makino Y; Shibazaki S; Hamaguchi T
    BMC Gastroenterol; 2023 Oct; 23(1):339. PubMed ID: 37784019
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Mutation Profile via Next-Generation Sequencing in Patients with colorectal Adenocarcinoma and Its Clinicopathological Correlation.
    Osman S; Kahraman Çetin N; Erdoğdu İH; Meteoğlu İ
    Turk J Gastroenterol; 2023 Nov; 34(11):1124-1133. PubMed ID: 37737217
    [TBL] [Abstract] [Full Text] [Related]  

  • 20.
    Liu Y; Sun M; Zhang B; Zhao W
    Aging (Albany NY); 2023 Sep; 15(17):9182-9192. PubMed ID: 37708299
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 43.